Clinical Trials

29 enrolled 9 charts

Colonic Neoplasms, Colorectal Neoplasms

NCT02130466 2022-08-01

MK-3475-022

Phase 1/2 Completed

184 enrolled 62 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT01336634 2022-04-04

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

177 enrolled 19 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01989598 2022-03-02

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

25 enrolled 11 charts

Plasma cell

Multiple Myeloma

NCT02083354 2022-02-01

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

77 enrolled 43 charts

Melanoma, Neoplasms, Skin Neoplasms

NCT01750918 2021-10-29

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

Phase 1/2 Completed

166 enrolled 46 charts

139 enrolled 42 charts 2 FDA

Neoplasms, Colorectal Neoplasms

NCT02124772 2021-07-14

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Phase 1/2 Completed

CNSMyeloid

Histiocytosis, Langerhans-Cell, Neoplasms, Neuroblastoma, Neurofibroma, Plexiform

NCT02296112 2021-05-28

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

9 enrolled 14 charts

Melanoma

NCT01597908 2021-02-24

COMBI-v

Phase 3 Completed

704 enrolled 13 charts

Melanoma, Neoplasms

NCT01584648 2021-02-17

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Phase 3 Completed

423 enrolled 15 charts

Melanoma

NCT01941927 2020-02-12

Trametinib With GSK2141795 in BRAF Wild-type Melanoma

20 enrolled 16 charts

Melanoma

NCT01964924 2019-09-20

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

37 enrolled 17 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01072175 2019-07-05

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

430 enrolled 61 charts

Melanoma, Neoplasms

NCT02039947 2019-05-21

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

127 enrolled 17 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01245062 2018-04-05

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Phase 3 Completed

322 enrolled 24 charts

Melanoma, Neoplasms

NCT02042443 2017-09-12

S1310

53 enrolled 13 charts

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Cholangiocarcinoma, Klatskin Tumor

NCT01928940 2017-07-24

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

12 enrolled 28 charts

Melanoma

NCT01943864 2017-05-31

A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers

20 enrolled 27 charts

Biliary Tract Neoplasms, Neoplasms

NCT01553851 2016-12-26

GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer

20 enrolled 13 charts

Head & Neck

Mouth Neoplasms

NCT01619774 2016-12-12

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

28 enrolled 7 charts

Melanoma

NCT01362296 2014-07-11

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

134 enrolled 22 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00920140 2014-04-02

Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

Other hematologic neoplasm

97 enrolled 23 charts

Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT01037127 2014-03-31

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

97 enrolled 18 charts

Melanoma, Neoplasms

NCT01231581 2013-09-26

Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer